Tempest Therapeutics, Inc. Share Price & Technical Analysis
TPST · $1.92 (-1.03%)
Healthcare / Biotechnology
$1.92
-1.03%
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-149…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-5% return in May, -17% avg return in past 3 year May month.
-29% return in 2026, 318% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -7% | -15% | -27% | 25% | -5% | – | – | – | – | – | – | – | -29% |
| 25 | 9% | -9% | -10% | -25% | -17% | 13% | 6% | 38% | 6% | -1% | -69% | -9% | -69% |
| 24 | -13% | -2% | 2% | -12% | -4% | -35% | -17% | -28% | 12% | -36% | 5% | -12% | -140% |
| 23 | 67% | -10% | 32% | -9% | -30% | -21% | -24% | -46% | -43% | 1233% | -13% | 26% | 1164% |
| 22 | -26% | -20% | -2% | 11% | -12% | -24% | -6% | 4% | -18% | 2% | -16% | -27% | -135% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$27.25M
P/E ratio
—
52W high
$12.23
52W low
$1.50
Volume
59,273
Beta
-1.69
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Tempest Therapeutics, Inc. share price today?
- Tempest Therapeutics, Inc. (TPST) last traded around $1.92 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TPST have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TPST. Download the app for real-time alerts.
- How can I analyze Tempest Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.